Research Study

A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics
Principal Investigator 
Vincent C. Ho

Overview

Body Locations and Systems 
Psoriasis
ClinicalTrials.gov# 
NCT00508547
Status 
Closed to Recruitment
Study Start/End 
Jul 6, 2009 to Jun 30, 2017
Locations 
Vancouver General Hospital
Name/Title 
Jaspal Mor, Clinical Trial Coordinator
Phone 
604-875-5296
Email Address 
jaspal.mor@ubc.ca
Purpose of Study 

The purpose of this study is to further evaluate the safety of infliximab and ustekinumab in patients with plaque psoriasis, and other all forms of psoriasis (such as plaque psoriasis and psoriatic arthritis occurring together). The registry study will track the behavior of the disease in response to other therapies, such as other biologic drugs. The registry will also evaluate clinical outcomes; disease characteristics, including physician reported assessment of psoriatic arthritis (PsA); quality of life, and potential risks for patients who may receive standard therapies for psoriasis.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.